نتایج جستجو برای: myelogenous leukemiablood cancer

تعداد نتایج: 915870  

Journal: :American Journal of Clinical Pathology 1996

Journal: :Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology 2010
Elizabeth Vogel Taylor Jennifer A Fortune Catherine L Drennan

Here, we present a six-session laboratory exercise designed to introduce students to standard biochemical techniques in the context of investigating a high impact research topic, acquired resistance to the cancer drug Gleevec. Students express a Gleevec-resistant mutant of the Abelson tyrosine kinase domain, the active domain of an oncogenic protein implicated in chronic myelogenous leukemia, a...

2003
Nancy U. Lin Stefanie Sarantopoulos James R. Stone Ilene Galinsky Richard M. Stone Robert J. Soiffer

1. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935-942. 2. Hoelzer D, Gokbuget N, Ottman OG. Targeted therapies in the treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia. Semin Hematol. 2002;39(suppl 3):32-37. 3. Dager R, Cohen M, Williams G, et al. Appr...

2011
Elizabeth Vogel Taylor Jennifer A. Fortune Catherine L. Drennan

Here, we present a six-session laboratory exercise designed to introduce students to standard biochemical techniques in the context of investigating a high impact research topic, acquired resistance to the cancer drug Gleevec. Students express a Gleevec-resistant mutant of the Abelson tyrosine kinase domain, the active domain of an oncogenic protein implicated in chronic myelogenous leukemia, a...

Journal: :Acta medica Okayama 1984
B S Kim

We have studied the incidence pattern of childhood cancers in Korea. Although the incidence of many tumors in Korea is similar to that in other countries, the incidence of acute myelogenous leukemia, non-Hodgkin's lymphoma and hepatoma is greater in Korean children. Yonsei Cancer Center commenced a study of multi-modality treatment of childhood cancers in July 1974. The most striking improvemen...

Journal: :Journal of health care for the poor and underserved 2013
Joël Ladner Ebru Tekinturhan Marie-Pierre Tavolacci Etienne Audureau Joseph Saba

BACKGROUND The Glivec International Patient Assistance Program (GIPAP) is designed to provide access to the cancer therapy Imatinib (Glivec⊠), which is indicated for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). OBJECTIVES To identify factors those influence the quality of care and structural improvements. Design . Physicians (n=50), hospital ...

Journal: :Molecular pharmacology 1999
V E Kagan J C Yalowich G G Borisenko Y Y Tyurina V A Tyurin P Thampatty J P Fabisiak

Etoposide (VP-16) is extensively used to treat cancer, yet its efficacy is calamitously associated with an increased risk of secondary acute myelogenous leukemia. The mechanisms for the extremely high susceptibility of myeloid stem cells to the leukemogenic effects of etoposide have not been elucidated. We propose a mechanism to account for the etoposide-induced secondary acute myelogenous leuk...

Journal: :Atlas of Genetics and Cytogenetics in Oncology and Haematology 2010

Splenic infarction occurs due to occlusion of splenic vessels that leads to splenic tissue ischemia and necrosis. There are several reports regarding splenic infarction in patients with acute myelogenous leukemia (AML). Herein, we report a case of acute promyelocytic anemia (AML-M3) who presented with abdominal pain and splenic infarction.

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید